Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1416833 | 0.82 | NPC1 (0.50) | NPSR1KDM4ENPC1RAB9ATRPV3 | |
| SCHEMBL31114090 | 0.81 | CASP3 (0.44) | NPSR1KDM4EKIF11KMT2ANPC1 | |
| SCHEMBL28510482 | 0.81 | CYP11B1 (0.43) | NPSR1KDM4EKIF11KMT2AMAOB | |
| SCHEMBL31114170 | 0.81 | CYP11B1 (0.43) | NPSR1KDM4EKIF11KMT2AMAOB | |
| SCHEMBL16915425 | 0.81 | HSD17B10 (0.48) | NPSR1KDM4EKIF11KMT2ANPC1 | |
| SCHEMBL11272729 | 0.79 | KMT2A (0.51) | NPSR1KDM4EKIF11KMT2AHPGD | |
| SCHEMBL13247920 | 0.78 | MAPT (0.47) | NPSR1KDM4EKIF11KMT2ANPC1 | |
| SCHEMBL29595709 | 0.78 | NPSR1 (0.53) | NPSR1KDM4EKIF11KMT2ANPC1 | |
| SCHEMBL811160 | 0.78 | NPSR1 (0.53) | NPSR1KDM4EKIF11KMT2ANPC1 | |
| SCHEMBL31676875 | 0.76 | RAB9A (0.46) | NPSR1KDM4EKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890937-B2 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-03-11 | — | — | US | disclosed |
| US-6541489-B1 | Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1 | G. D. SEARLE & COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2002-11-28 | — | — | US | disclosed |
| CN-1370144-A | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2002-09-18 | — | — | CN | disclosed |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | PHARMACIA CORPORATION | 2001-11-08 | — | — | US | disclosed |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | BARTA THOMAS E (US) | 2001-08-16 | — | — | US | disclosed |
| CN-1279669-A | Aromatic sulfone hydroxamic acid metalloprotease inhibitors | SEARLE & CO (US) | 2001-01-10 | — | — | CN | disclosed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP10 | NPSR1 2790/4885KDM4E 461/4885KIF11 1715/4885 |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | NPSR1 2790/4885KDM4E 461/4885KIF11 1715/4885 |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP9, MMP1, MMP13 | NPSR1 1306/4885KDM4E 768/4885KIF11 2599/4885 |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | NPSR1 2790/4885KDM4E 461/4885KIF11 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.